- Conditions
- Chronic Urticaria
- Interventions
- Stress intervention
- Behavioral
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 96
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064 (blinded), placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 11
- States / cities
- Bakersfield, California • San Diego, California • Miami, Florida + 8 more
- Conditions
- Cryopyrin-Associated Periodic Syndromes, Amyloidosis
- Interventions
- 124I AT-01
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ligelizumab
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 14 more
- Conditions
- Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Interventions
- Canakinumab (ACZ885)
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more
- Conditions
- Hypersensitivity, Immediate, Autoinflammatory Syndromes, Physical Urticaria, Familial Cold Autoinflammatory Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 90 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Standard of Care
- Biological · Other
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 32 more
- Conditions
- Urticaria
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 40
- States / cities
- Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- etanercept, placebo
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Urticaria
- Interventions
- GDC-0853
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 7 more
- Conditions
- Chronic Urticaria, Idiopathic
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Muckle Wells Syndrome
- Interventions
- ACZ885, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 4 Years to 75 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Madison, Wisconsin
- Conditions
- Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
- Interventions
- KPL-716, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
- Conditions
- Chronic Inducible Urticaria
- Interventions
- Remibrutinib, Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 21 more
- Conditions
- Urticaria
- Interventions
- Xolair® (Omalizumab)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Kirksville, Missouri
- Conditions
- Urticaria, Angioedema, Hives, Swelling
- Interventions
- High Dose Vitamin D3, Low Dose Vitamin D3
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Healthy Participants, Chronic Spontaneous Urticaria
- Interventions
- AK006-IV, Placebo-IV, AK006-SC, Placebo-SC
- Drug
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more
- Conditions
- Chronic Inducible Urticaria
- Interventions
- Oral EP262
- Drug
- Lead sponsor
- Escient Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Boise, Idaho • Owensboro, Kentucky + 4 more
- Conditions
- Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
- Interventions
- Povorcitinib, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more
- Conditions
- Cryopyrin-Associated Periodic Syndrome
- Interventions
- ATI-450
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- San Diego, California • San Francisco, California
- Conditions
- Urticaria, Angioedema
- Interventions
- Not listed
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Matching placebo
- Biological
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 976 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 63
- States / cities
- Cullman, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 47 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064 (blinded), Placebo, LOU064 (open label)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 38 more